StockNews.AI
ABT
StockNews.AI
112 days

Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information

1. Abbott integrates FreeStyle Libre CGM data with Epic's electronic health records. 2. Integration aims to streamline workflows for over 575,000 U.S. healthcare providers. 3. The collaboration enhances diabetic care by reducing administrative hurdles. 4. Abbott plans further integration with other medical devices in the future. 5. Libre systems currently serve over 7 million patients globally.

8m saved
Insight
Article

FAQ

Why Bullish?

This strategic collaboration enhances Abbott's offerings in digital healthcare, likely boosting sales and market confidence. Historical examples show that successful integrations often lead to increased revenue and consumer trust, which positively impacted other med-tech stocks in similar situations.

How important is it?

This integration significantly aligns with current market trends focusing on digital health solutions, making it important for investors. The potential for expanding the integrated model to other medical devices showcases Abbott's forward-thinking strategy, which could enhance its market position.

Why Long Term?

The benefits from this integration will likely grow as more healthcare systems adopt it, translating to sustained revenue growth for Abbott in the long run, similar to past expansions seen in the healthcare technology sector.

Related Companies

AAPLMDTETRSENSDHR
Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows , /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading1 Libre CGM systems directly into Epic's electronic health record systems in the U.S. The collaboration aims to improve workflow efficiency for providers through Epic's Aura software, which brings health systems together with diagnostics labs and medical device manufacturers. Through this integration, data from a user's LibreView† account can be automatically linked to Epic, allowing clinicians to effortlessly view their patients' glucose data within Epic before, during and after meeting with their patients. This seamless process ensures healthcare providers can access key glucose data directly within their preferred workflows, enabling more informed care. "Our goal is to simplify care and drive better outcomes for both providers and patients," said Lisa Earnhardt, executive vice president and group president of medical devices for Abbott. "While the integration with Libre data is Abbott's first medical device offering with Epic, it's just the beginning. We aim to expand this model to our other medical devices and connected care platforms in the future." Now, more than 575,000 U.S. healthcare providers serving 2802 million patients will have access to critical glucose data in their patients' charts, helping them spend less time finding data and more time on care management. With Libre systems and Epic, patients can more easily collaborate with their providers and utilize advanced CGM technology that can lead to improved patient engagement and behavior change* 3,4,5. "Our work with Abbott aims to make life simpler for the nearly 40 million people in the U.S. who live with diabetes today6," said Alan Hutchison, vice president at Epic. "Diabetes requires close collaboration between patients, primary care providers, and specialists to manage a complex and time-critical care plan. This will help everyone focus more on patient care and less on administrative hurdles." Healthcare providers and health system administrations who would like to receive future updates on this integration can email Abbott's diabetes care business at [email protected]. About FreeStyle Libre:Abbott continues to pioneer ground-breaking technology to support people living with diabetes. The company revolutionized diabetes care 10 years ago with its world-leading FreeStyle Libre continuous glucose monitoring portfolio1, which today is used by more than 7 million people across over 60 countries7. People use Libre technology to see their glucose numbers in real-time, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals. There is full or partial reimbursement for Libre systems in more than 40 countries7. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.   For important safety information, visit https://www.freestylelibre.us/safety-information.html * Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 3 and 2 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.†The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice. Data on file, Abbott Diabetes Care. Based on the number of patients assigned to each manufacturer.  According to data provided by Definitive HealthcareTM and Epic. Huang, Eileen, Mohamed Nada, and Eugene Wright, Jr. "73-LB: Ambulatory Glucose Profile Informs Better Treatment Decisions for Type 2 Basal-Insulin Patients." Diabetes 71, no. Supplement_1 (2022): 73–LB. https://doi.org/10.2337/db22-73-LB. Haak, Thomas, et al. "Flash Glucose-sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55–73. https://doi.org/10.1007/s13300-016-0223-6 Fokkert, Marion, et al. "Improved Well-Being and Decreased Disease Burden After 1-Year Use of Flash Glucose Monitoring (FLARE-NL4)." BMJ Open Diabetes Research and Care 7, no. 1 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. Centers for Disease Control and Prevention, National Diabetes Statistics Report, accessed April 11, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html.    Data on file, Abbott Diabetes Care.  SOURCE Abbott WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News